Organization (Industry)
TEVA PHARMACEUTICAL INDUSTRIES LTD
ClinicalTrials.gov lists TEVA PHARMACEUTICAL INDUSTRIES LTD as lead sponsor of 288 trials, counting the companies grouped under it. TEVA PHARMACEUTICAL INDUSTRIES LTD itself has 1 approved asset.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. Companies grouped under this one are not included. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Logo רונאלדיניו המלך, via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers TEVA PHARMACEUTICAL INDUSTRIES LTD and 9 companies grouped under it: 288 lead-sponsored trials (4 its own, 284 in the grouped companies) and 4 legal-entity registrations (1 its own, 3 in the grouped companies).
Companies grouped under this page (9)
Shown in this order: most lead trials first.
| Company | Lead trials | Legal entities |
|---|---|---|
| Teva Pharmaceuticals USA | 176 | 0 |
| Actavis Inc. | 95 | 0 |
| NORTON HEALTHCARE, INC. | 7 | 2 |
| Actavis Mid-Atlantic LLC | 4 | 0 |
| Barr Laboratories | 1 | 0 |
Showing 5 of 9 member companies.
Disease areas (23)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Osteoarthritis | 7 |
| Osteoarthritis, Knee | 6 |
| Osteoarthritis, Hip | 5 |
| Parkinson Disease | 2 |
| Alzheimer Disease | 1 |
Showing 5 of 23 disease areas.
Trials by start year as sponsor or collaborator (11)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2022 | 1 |
| 2020 | 1 |
| 2019 | 2 |
| 2018 | 1 |
| 2017 | 3 |
| 2016 | 2 |
| 2015 | 1 |
| 2014 | 4 |
| 2010 | 1 |
| 2006 | 1 |
Showing 10 of 11 years.
Recruitment duration, a model prediction: none of the 4 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Approved assets (1)
| Drug | Trials |
|---|---|
| Somatropin | 1 |
Journals published in (5)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Acta neuropathologica | 1 |
| BMC musculoskeletal disorders | 1 |
| EBioMedicine | 1 |
| Osteoarthritis and cartilage | 1 |
| RMD open | 1 |
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 517 | 5 | 2025-05-27 |
SEC-reported annual financials (10)
Shown in this order: newest fiscal year first; SEC EDGAR XBRL companyfacts, USD as reported.
| Fiscal year | Revenue (USD) | Net income (USD) | R&D (USD) |
|---|---|---|---|
| 2025 | 17,258,000,000 | 1,410,000,000 | 1,013,000,000 |
| 2024 | 16,544,000,000 | -1,639,000,000 | 998,000,000 |
| 2023 | 15,846,000,000 | -559,000,000 | 953,000,000 |
| 2022 | 14,925,000,000 | -2,446,000,000 | 838,000,000 |
| 2021 | 15,878,000,000 | 417,000,000 | 967,000,000 |
| 2020 | 16,659,000,000 | -3,990,000,000 | 997,000,000 |
| 2019 | 16,887,000,000 | -999,000,000 | 1,010,000,000 |
| 2018 | 18,271,000,000 | -2,150,000,000 | 1,213,000,000 |
| 2017 | 21,853,000,000 | -16,265,000,000 | 175,000,000 |
| 2016 | 21,903,000,000 | 329,000,000 | 422,000,000 |
Financing and grant events (21)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2026-04-29 | Other financing | not disclosed | Sec extracted |
| 2025-12-10 | Debt financing | not disclosed | Sec extracted |
| 2025-05-28 | Debt financing | 1,200,000,000 | Sec extracted |
| 2025-05-22 | Debt financing | not disclosed | Edgar offerings |
| 2025-05-20 | Debt financing | not disclosed | Sec extracted |
Showing 5 of 21 events.
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| VAI | 15 |
FDA recalls (1)
| Product | Classification | Initiated |
|---|---|---|
| Irbesartan and Hydrochlorothiazide tablets USP 150 mg/ 12.5 mg, 90-count bottles, Rx only, Manufactured in Israel by: TEVA PHARMACEUTICAL INDUSTRIES LTD Jerusalem, 971010 Israel, Manufactured for: TEVA PHARMACEUTICAL INDUSTRIES USA Sellersville, PA 18960. NDC 0093-8238-98 | Class III | 2015-10-20 |
FDA import refusals (1)
| Refused import lines | Latest refusal |
|---|---|
| 35 | 2026-06-23 |
Manufacturing and distribution sites (26)
Shown in this order: severity rank then name.
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| Teva Canada Limited | Scarborough, CA | FDA, Health Canada | Teva Canada Limited |
| Teva Czech Industries s.r.o. | Opava, CZ | EMA, FDA, Health Canada | Teva Czech Industries s.r.o. |
| Barr Laboratories LLC | Forest, US | FDA, Health Canada | Barr Laboratories Inc. |
| Teva Canada Limited | Markham, CA | FDA, Health Canada | Teva Canada Limited |
| Norton Healthcare Limited | Runcorn, GB | FDA | Norton Healthcare Limited |
Showing 5 of 26 sites.
Climate targets, as filed (1)
| Reporting year | Net-zero target |
|---|---|
| 2025 | 2045 |
Workforce and board diversity, as filed (1)
| Reporting year | Workforce % women | Board % women |
|---|---|---|
| 2025 | not disclosed | not disclosed |
Organization relationships (8)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Evotec SE | Co sponsors trial with | 1 |
| University of Pennsylvania | Co sponsors trial with | 1 |
| Fondation Ophtalmologique Adolphe de Rothschild | Co sponsors trial with | 1 |
| Government of the United States of America | Co sponsors trial with | 1 |
| Quotient Sciences Limited (United Kingdom) | Co sponsors trial with | 1 |
Showing 5 of 8 relationships.
Latest dated events (607)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-06-23 | FDA import refusal | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2026-04-29 | Financing | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2025-12-10 | Debt facility | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2025-05-28 | Debt facility | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2025-05-27 | Patent granted | Granted US patents (PatentsView / USPTO) |
Showing 5 of 607 events.
Biomarker capability evidence (26)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| LBP | Trial collaborator | Named in trial inclusion criteria |
| LBP | Trial collaborator | Primary endpoint in a Phase 3 trial |
| PTGS2 | Trial collaborator | Named in trial inclusion criteria |
| PTGS2 | Trial collaborator | Named in trial inclusion criteria |
| CYP1A2 | Trial collaborator | Named in trial exclusion criteria |
Showing 5 of 26 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: related companies not grouped here, active development programs, sponsor delivery record, fda warning letters, fda untitled letters, clia clinical laboratory certificates, and biomarkers this organization publishes on.